A- A A+

Substitutionsbericht 2018 und Marktzahlen für Substitutionsmedikamente

Anmerkungen zum Substitutionsbericht des BfArM für 2018 und Zahlen und Daten zum Pharmamarkt für Substitutionsmedikamente in Deutschland. (Forum Substitutionspraxis, 12.03.2019)

Substitutionsbericht 2018 und Marktzahlen für Substitutionsmedikamente

USA. OxyContin maker Purdue Pharma exploring bankruptcy

Filing for Chapter 11 protection would halt the thousands of lawsuits alleging the drug manufacturer used deceptive practices to push addictive drugs that led to fatal overdoses. (NBC News, USA, 04.03.2019)


WHO. Philip Morris-funded FSFW fails (again) to end pariah status

The Philip Morris-funded Foundation for a Smoke-Free World published an open letter to the Board of the WHO on 24 January 2019, urging it to ‘consider how best to work with the Foundation’. The letter was published to coincide with the WHO January Executive board meeting. The WHO stance since September 2017 has been that it will not partner with FSFW, governments should not partner with FSFW, and the public health community should follow this lead. (Hefler M, Worldwide news and comment, Tobacco Control 2019;28:123-126.)


USA. Juul Expects Skyrocketing Sales of $3.4 Billion, Despite Flavored Vape Restrictions

The e-cigarette maker forecasts revenue that would nearly triple from last year. (Bloomberg, USA, 22.02.2019)


USA. Sackler Embraced Plan to Conceal OxyContin's Strength From Doctors, Sealed Testimony Shows

In May 1997, the year after Purdue Pharma launched OxyContin, its head of sales and marketing sought input on a key decision from Dr Richard Sackler, a member of the billionaire family that founded and controls the company. Michael Friedman told Sackler that he didn't want to correct the false impression among doctors that OxyContin was weaker than morphine, because the myth was boosting prescriptions — and sales. (Medscape, USA, 21.02.2019)


USA. Drug company used rap video to push for higher doses, sales

Employees at a drug company accused of bribing doctors rapped and danced around a person dressed as a bottle of the highly addictive fentanyl spray in a video meant to motivate sales reps into getting patients on higher doses. (MedicalXpress, USA, 15.02.2019)


USA. This complaint shows Purdue Pharma’s secret plan to perversely profit by both creating and treating addiction

Making billions off a pain pill whose promotion helped spawn the prescription opioid epidemic that grew into today’s overdose fatality crisis wasn’t enough for the Sackler family, the owners of Purdue Pharma, the manufacturer of OxyContin. Seeing their profits starting to fall off in the face of growing resistance to their hyper-aggressive marketing of the drug, the Sacklers plotted to turn the misery of addiction they helped create into a cash cow for the company by acquiring and selling drugs aimed at treating that addiction. (AlterNet, USA, 11.02.2019)


USA. The Big Pharma Family that Brought Us the Opioid Crisis - Who will bring to justice the billionaires who have profited so royally from addiction? 

If the devil wears Prada, what do America’s most destructive drug pushers wear? They wear smiles. (inequality.org, USA, 16.02.2019)


Tabakindustrie: Deutsche rauchen öfter Zigarre 

Der Absatz von Zigaretten ist in Deutschland leicht gesunken. Das heißt aber nicht unbedingt, dass es weniger Raucher gibt. (Spiegel online, 14.01.2019)


USA. Sackler Scion’s Email Reveals Push for High-Dose OxyContin, New Lawsuit Disclosures Claim

A member of the Sackler family that owns OxyContin’s maker directed the company to put a premium on selling high dosages of its potentially addicting painkillers, according to new disclosures in a lawsuit. (New York Times, 31.01.2019)


The European Cannabis Report™ 4th Edition

Home to more than 740 million people, a population more than double that of the United States and Canada combined, Europe is set to become the world’s largest legal cannabis market over the next five years. In the last 12 months alone, the European cannabis industry has grown more than in the last six years. Six countries have announced new legislation and over €500m has been invested in European cannabis businesses and as our exclusive research shows, Europe’s cannabis market is estimated to be worth up to €123bn by 2028. (Prohibition Partner’s, London/Barcelona, Januar 2019)


Verbände fordern umfassendes Werbeverbot für Tabakprodukte und E-Zigaretten

Tabakwerbung und die Werbung für E-Zigaretten ist insbesondere für Jugendliche und auch Kinder attraktiv und macht ein umfassendes Verbot unumgänglich. Studien zeigen, dass insbesondere junge Menschen auf Tabakaußenwerbung reagieren – 75 Prozent der Jugendlichen und jungen Erwachsenen nehmen diese wahr. Besonders ins Auge fallen dabei Plakatwände. Neben dem Freundeskreis ist Zigarettenwerbung der häufigste Grund für junge Menschen, mit dem Rauchen anzufangen. Stärker als bei anderen Produkten haben Studien eine klare Verbindung zwischen der Wahrnehmung von Zigarettenwerbung und dem Rauchverhalten festgestellt. Dabei zeigen Tabakwerbeverbote Wirkung: In Ländern mit umfassenden Verbotsregelungen ist ein deutlich größerer Rückgang des Tabakkonsums zu verzeichnen. Allerdings funktioniert das vor allem dann, wenn Werbeverbote umfassend sind.

Ein Bündnis von 13 Verbänden und Organisationen fordert daher ein umfassendes Werbeverbot für Tabakprodukte und E-Zigaretten. Neben dem Deutschen Kinderhilfswerk, der Deutschen Krebshilfe, dem Deutschen Krebsforschungszentrum, dem IFT Nord und der Deutschen Allianz Nichtübertragbarer Krankheiten haben u.a. das Netzwerk rauchfrei plus, die Fachstelle für Suchtprävention Berlin, der Ärztliche Arbeitskreis Rauchen und Gesundheit, die Verbraucherorganisation SumOfUs und das Projekt Unfairtobacco den Appell unterzeichnet. (berlin-suchtpraevention.de, 29.01.2019)


Tabakplakatwerbung in Deutschland besonders präsent

Heidelberg – Tabakwerbung auf Plakatwänden ist in Deutschland wesentlich präsenter als in anderen Ländern. Das geht aus einer neuen Untersuchung des Deutschen Krebsforschungszentrums (DKFZ) in acht europäischen Ländern hervor. (aerzteblatt.de, 29.01.2019)


Israel erlaubt Export von medizinischem Cannabis

Tel Aviv – Rund 35.000 Patienten in Israel lassen sich mit medizinischem Cannabis behandeln. Nun will das Land solche Produkte auch exportieren, wie die Regierung vorgestern beschloss. (aerzteblatt.de, 29.01.2019)


USA: Studie macht Pharmamarketing für Anstieg der Opioid-Todesfälle mitverantwortlich

Boston – Ein kostenloses Essen für den Arzt oder andere Geschenke des Pharma­marketings könnten den Drogentod einzelner Patienten fördern. In den USA kam es laut einer Studie in JAMA Network Open(2019; 2: e186007) in den letzten Jahren überall dort zu überdurchschnittlich vielen Todesfällen durch Opioid-Überdosierungen, wo die Ärzte besonders intensiv von den Herstellern umworben wurden. (aerzteblatt.de, 21.01.2019)


USA. Sacklers Directed Efforts to Mislead Public About OxyContin, New Documents Indicate

A filing in a Massachusetts lawsuit contains dozens of internal Purdue Pharma documents suggesting the family was far more involved than the company has long contended. (New York Times, 15.01.2019)


Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses.

Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. 

JAMA Netw Open.2019;2(1):e186007. doi:10.1001/jamanetworkopen.2018.6007


USA. County By County, Researchers Link Opioid Deaths To Drugmakers’ Marketing

Researchers sketched a vivid line Friday linking the dollars spent by drugmakers to woo doctors around the country to a vast opioid epidemic that has led to tens of thousands of deaths.

The study, published in JAMA Network Open, looked at county-specific federal data and found that the more opioid-related marketing dollars were spent in a county, the higher the rates of doctors who prescribed those drugs and, ultimately, the more overdose deaths occurred in that county. (KHN – Kaiser Health News, USA, 18.01.2019)


USA. Despite Conflicting Evidence, A New Report Finds Legal Marijuana Does Not Impact Alcohol Sales

Weighing in on an issue that weighs heavily on alcoholic beverage suppliers, the Distilled Spirits Council released new research that shows the sale of legalized marijuana does not impact alcohol purchases, at least in the three states that have allowed recreational pot smoking the longest. (Forbes, USA, 10.01.2019)


USA. Congressional report: DEA, drug distributors failed to stop flow of opioids into West Virginia

The Drug Enforcement Administration and some of the country’s largest drug distributors failed to stop a massive flow of opioids into rural West Virginia over the past 10 years, according to a new congressional report.

According to the bipartisan report, prepared by the House Energy and Commerce Committee majority staff, the distributors did not conduct proper oversight of their customers and failed to recognize potential red flags. Distributors transfer drugs from manufacturers to businesses such as clinics, hospitals, and pharmacies, where they can be dispensed to patients. 

Those failures helped contribute to the worsening opioid epidemic in West Virginia, “the epicenter of the nation’s opioid epidemic and the state with the highest drug overdose death rate in the country,” the report says.

The report found that three of the country’s largest distributors did not question suspicious orders and did not monitor the volume of controlled substances sold to customers. (The Hill, USA, 19.12.2018)


USA. The National Cannabis Economy


The growth of the cannabis economy presents opportunities for greater job creation, more tax revenue, and better patient care. But current conflicts between state and federal law threaten to impede social and economic growth. Going forward, lawmakers and regulators should prioritize solutions that promote greater research into the health effects of cannabis and reduce regulations that restrict the industry’s ability to conduct business. (Democratic Staff of the Joint Economic Committee, USA, Senat, Dezember 2018)


USA. Opioid-Makers Face Wave of Lawsuits in 2019

The next 12 months might just redefine the way America thinks about and responds to the opioid epidemic that now claims more than 40,000 lives each year. The nation's biggest drugmakers and distributors face a wave of civil lawsuits that could total tens of billions of dollars in damages. (NPR – National Public Radio, USA. 31.12.2018)


USA. Indivior Plans Cheaper Opioid Addiction Drug if Rivals Launch Copycats

Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug. (psychcongress.com, USA, 16.12.2018)


Asien drängt in das Milliarden-Geschäft mit Cannabis 

Während im Westen eine neue Industrie entsteht, wird der Cannabis-Konsum in Asien noch hart bestraft. Jetzt liberalisieren die Staaten ihre Gesetze. (Handelsblatt, 22.12.2018)


USA. US-Tabakkonzern Altria steigt bei E-Zigaretten-Anbieter Juul ein

Washington – Der US-Tabakkonzern Altria mit Marken wie Marlboro und Chesterfield steigt für 12,8 Milliarden Dollar (11,2 Milliarden Euro) beim E-Zigaretten-Hersteller Juul ein. (aerzteblatt.de, 21.12.2018)


Global. Tilray Inc.: Ten internationally-renowned business and government leaders to advise company on global expansion 

NANAIMO, B.C. – Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced the formation of its International Advisory Board, an esteemed group of business and government leaders who will provide guidance to Tilray’s executive team and Board of Directors as the company pursues its aggressive global growth strategy. 

(...) Joschka Fischerserved as Foreign Minister and Vice Chancellor of the Federal Republic of Germany. He is a member of the Executive Board of the European Council on Foreign Relations. Mr. Fischer also currently serves as Managing Partner of Joschka Fischer & Company, a global strategy firm, where he advises clients on issues relating to Germany and the European Union. (Tilray Inc., Kanada, 12.12.2018)


Kanada. AB InBev and Tilray Announce Research Partnership Focused on Non-Alcohol THC and CBD Beverages - New Partnership to Focus on Research that will Guide Responsible Innovation.

TORONTO, CANADA – December 19, 2018 –Today, AB InBev, the world’s leading brewer, and Tilray, a global pioneer in cannabis production and distribution, announced a partnership to research non-alcohol beverages containing tetrahydrocannabinol (THC) and cannabidiol (CBD). The partnership is limited to Canada and decisions regarding the commercialization of the beverages will be made in the future. (Tilray Inc., Kanada, 19.12.2018)


Global. Tilray® Signs Global Collaboration Agreement with Leading Pharmaceutical Company -- Tilray Inc. announced today that it entered into a global framework agreement (the “Framework Agreement”) to collaborate with Sandoz AG.

NANAIMO, B.C.– Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ: TLRY), a global pioneer in the production, research, and distribution of medical cannabis, announced today that it entered into a global framework agreement (the “Framework Agreement”) to collaborate with Sandoz AG, a global leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high quality medical cannabis products across the world. (Tilray Inc., Kanada, 18.12.2018)


Umstrittene E-Zigarette kommt nach Deutschland

Washington/Hamburg – Ab heute wird die stark nikotinhaltige und daher umstrittene E-Zigarette Juul aus den USA auch in Deutschland erhältlich sein. Im Gegensatz zu den USA enthält die E-Zigarette hierzulande laut der Tabakproduktrichtlinie mit 20 Milligramm pro Milliliter weniger als die Häfte an Nikotin als das ursprüngliche US-Produkt. Die US-Gesundheitsbehörde FDA hatte vor Juul gewarnt – insbesondere auch wegen der vielen Schüler, die an Juul ziehen. (aerzteblatt.de, 19.12.2018)